Environment Social Governance - ESG | Swixx BioPharma

Environment Social Governance - ESG

The year 2024 marked an important milestone for Swixx Biopharma. As we celebrated our 10th anniversary, we also introduced our ESG framework, developed through extensive stakeholder engagement. The framework reflects our responsible, compliant, sustainable, and ethical approach to business and defines five ESG building blocks aligned with the UN Sustainable Development Goals:

Put People First – promoting collaboration, well-being, safety, diversity, inclusion, and equity in the workplace.
Ensure Access to Medicines – ensuring reliable supply of innovative therapies and diagnostics, expanding equitable access to care.
Strengthen Community Partnerships – empowering patient organizations and collaborating with stakeholders to improve health outcomes, particularly among vulnerable populations.
Preserve the Environment – implementing sustainable practices, responsible waste management, and reducing our environmental footprint.
Foster Sustainable Corporate Governance – reinforcing our culture of compliance while applying the highest standards of governance and ethics.

Building on this foundation, in 2025 we are proud to publish our first comprehensive ESG Report for 2024, which translates our commitments into concrete KPIs and demonstrates measurable progress. This report reflects not only what we have achieved but also our vision for the future: creating lasting value for patients, employees, communities, and the environment.
2024 ESG Highlights

100% of employees completed initial HSE training, strengthening workplace safety and awareness.
All Swixx warehouses now use certified waste service providers, reinforcing environmental stewardship.
4,427 diagnostic tests were performed through our rare disease program, expanding access to vital care.
Our Swixx Patient Academy pilot launched in two countries, empowering patient organizations and communities.
Swixx maintained ISO 37001 certification for Anti-Bribery Management System, underscoring our ethical standards.

Our ESG Journey
At Swixx Biopharma, sustainability is not a box to check but a continuous journey. The ESG framework provides the vision and direction, and our first ESG report demonstrates our progress with clarity and accountability.
We are guided by the belief that responsible business and lasting impact go hand in hand — and we will continue to improve lives ethically and sustainably, with unwavering dedication. Conscious of global efforts to integrate ESG into our business, we are dedicated to making a positive impact for our partners, patients, and communities.

ESG Strategy Framework (0.461 MB)

ESG Report 2024 (2.175 MB)

Swixx Biopharma becomes a “We Support” Endorser of the United Nations Global Compact

At the beginning of 2026, Swixx Biopharma is proud to announce that it has become a “We Support” Endorser of the United Nations Global Compact, the world’s largest corporate sustainability initiative.

This milestone marks a natural extension of Swixx Biopharma’s ESG framework and long-term commitment to responsible business practices. By supporting the UN Global Compact, the company reinforces its alignment with globally recognized standards and the principles that guide its operations across all markets.

The United Nations Global Compact calls on companies to align their strategies and operations with the Ten Principles, covering human rights, labour, environment and anti-corruption. These principles closely reflect Swixx Biopharma’s ESG priorities and its approach to ethical, transparent and sustainable business.

Launched in 2000, the United Nations Global Compact brings together more than 20,000 companies across over 160 countries, working toward a more sustainable, inclusive and responsible global economy.

By becoming a “We Support” Endorser, Swixx Biopharma is further strengthening its ESG commitments by:

Embedding ESG principles into its strategy and daily operations
Acting with integrity, transparency and accountability
Supporting broader societal goals, including the Sustainable Development Goals (SDGs)
Creating long-term value for patients, partners and the communities it serves

“Becoming a ‘We Support’ Endorser of the UN Global Compact is a natural step in our ESG journey. It reinforces our commitment to responsible business practices and to creating meaningful and sustainable impact across the markets we serve,” said Barbara Kosir, NED and ESG Ambassador.

Becoming an endorser is not just a milestone, it is a continuation of Swixx Biopharma’s journey to create meaningful and lasting impact.

About the United Nations Global Compact

The United Nations Global Compact is the world’s largest corporate sustainability initiative, calling on companies to align their strategies and operations with ten universal principles and to take actions that advance societal goals, including the Sustainable Development Goals (SDGs).

At the beginning of 2026, Swixx Biopharma became a “We Support” Endorser of the United Nations Global Compact, the world’s largest corporate sustainability initiative.

EcoVadis Awarded Swixx Biopharma Silver Medal for Sustainability Performance

Swixx BioPharma has been awarded a Silver Medal by EcoVadis in June 2026, recognizing the company’s continued progress in building a more sustainable and responsible business.